SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
ConditionNeisseria Gonorrhoeae Infection
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Washington
About this trial
This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
Eligibility criteria
Qualifiers
English speaking
Have access to the internet (via computer or phone) on at least a weekly basis
Asymptomatic (as defined below)
Disqualifiers
Urogenital symptoms consistent with a sexual transmitted infection (other than vaginitis associated with trichomonas vaginalis, bacterial vaginosis or yeast). Symptoms consistent with cervicitis, urethritis, or PID will not be offered enrollment.
Antibiotic use within the last 2 weeks
Contact to syphilis
Contact to an STI and are unwilling to defer empiric treatment until diagnostic test results return
Trial design
Treatments tested in this trial
- Ciprofloxacin 500 mg
Treatment groups
1,800 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov